


The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I




in which


- $R^1$  denotes ~~H, A, Hal,~~  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ ,  $CN$ ,  $C(NH)NOH$  or  $OCF_3$ ,
- $R^2$  denotes  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms ~~or~~  $CF_3$ ,
- $R^3, R^4$  denote H,  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_n$ Het,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nOOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  $(CH_2)_nN(R^5)C(R^5)HOOR^5$ ,  $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2OOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$  or  $(CH_2)_nN(R^5)Ar$ , where with the proviso that in each case one of the radicals  $R^3$  or  $R^4$  denotes H,
- $R^5$  denotes H or A,
- A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,
- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more heteroatoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,
- Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $OR^5$ ,  $OOCR^5$ ,  $COOR^5$ ,  $CON(R^5)_2$ ,  $CN$ ,  $NO_2$ ,  $NH_2$ ,  $NHCOR^5$ ,  $CF_3$  or  $SO_2CH_3$ ,

n	denotes 0, 1, 2, 3, 4 or 5,
Hal	denotes F, Cl, Br or I, and
X	denotes N, or

in the case where  $R^1$  denotes



in which R denotes H or an alkyl group having 1 to 6 C atoms,  
and/or R<sup>2</sup> denotes



in which R denotes H or an alkyl group having 1 to 6 C atoms,  
alternatively denotes CH<sub>3</sub>,  
~~or an a salt, solvate, enantiomer, racemate, or a mixture of enantiomers thereof,~~

or a pharmaceutically acceptable salt or solvate thereof.

2. (Previously Presented) A compound of formula I according to Claim 1, in which R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, -ethyl-, -n-propyl- or -n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, -dichloro- or -dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or -triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.


3. (Previously Presented) A compound of formula I according to claim 1, in which R<sup>3</sup> denotes H.

4. (Previously Presented) A compound of formula I according to claim 1, in which R<sup>4</sup> denotes H.

5. (Previously Presented) A compound of formula I according to claim 1, in which R<sup>2</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, -ethyl-, -n-propyl- or -n-butylphenyl, 2,3-, 2,4-, 2,5- or 2,6-difluoro- or -dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, or 2- or 3-pyrazinyl.

6. (Previously Presented) A compound of formula I according to claim 1, in which X denotes N.

7. (Currently Amended) A compound of formula IA, IB, IC, ID, IE or IF



in which

- $R^1$  denotes H, A, Hal,  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ , CN,  $C(NH)NOH$  or  $OCF_3$ ;
- $R^2$  denotes  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms or  $CF_3$ ;
- A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,
- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more heteroatoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,
- Ar denotes a phenyl radical which is unsubstituted or mono- or

polysubstituted by A and/or Hal,  $\text{OR}^5$ ,  $\text{OOCR}^5$ ,  $\text{COOR}^5$ ,  $\text{CON(R}^5)_2$ , CN,  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{NHCOR}^5$ ,  $\text{CF}_3$  or  $\text{SO}_2\text{CH}_3$ ,


$\text{R}^5$  denotes H or A,

n denotes 0, 1, 2, 3, 4 or 5,

Hal denotes F, Cl, Br or I, and


X denotes N, or

in the case where  $\text{R}^1$  denotes




in which R denotes H or an alkyl group having 1 to 6 C atoms,

and/or  $\text{R}^2$  denotes




in which R denotes H or an alkyl group having 1 to 6 C atoms,  
alternatively denotes CH,  
or a salt or solvate thereof.


8. (Previously Presented) A process for preparing a compound of  
formula IA according to claim 7



comprising reacting a compound of formula II




or an acid-addition salt thereof, in which  
R<sup>1</sup> and X have the meanings indicated for the compound of formula IA,  
with a compound of formula III



in which  
A and R<sup>2</sup> have the meanings indicated for the compound of formula IA,  
and/or  
a basic compound of formula IA is converted into one of its salts by treatment with an acid.


9. (Previously Presented) A process for preparing a compound of

formula IB according to claim 7



in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, X and A have the meanings indicated for the compound of formula IB,


comprising reacting a compound of formula II



or an acid-addition salt thereof, in which

R<sup>1</sup> and X have the meanings indicated for the compound of formula IB,

with a compound of formula IV



in which

A and R<sup>2</sup> have the meanings indicated for the compound of formula IB,

and/or

a basic compound of formula IB is converted into one of its salts by treatment with an acid.

10. (Previously Presented) A pharmaceutical composition comprising a compound of formula I according to claim 1 and a pharmaceutically acceptable carrier.

11. (Currently Amended) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound of formula I to 5 HT receptors, comprising administering to a subject in need thereof an effective amount of a

pharmaceutical composition according to claim 10.

12. (Previously Presented) A method for antagonizing a 5-HT receptor, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

13. (Previously Presented) A method for antagonizing a 5-HT<sub>2A</sub> receptor, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.


14. (Cancelled)

15. (Previously Presented) A process for preparing a pharmaceutical composition according to claim 10, comprising mixing together a compound of formula I and a pharmaceutically acceptable carrier.


16. (Currently Amended) A method for the ~~prophylaxis and/or~~ treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, eating disorder, bulimia, anorexia nervosa, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

17. (Currently Amended) A compound of claim 1, in which Het is one of the following groups






18. (Currently Amended) A compound of claim 7, in which Het is one of the following groups




19. (Previously Presented) A compound of formula I according to claim 1




in which

- $R^1$  denotes H, A, Hal,  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ , CN,  $C(NH)NOH$  or  $OCF_3$ ;
- $R^2$  denotes  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms or  $CF_3$ ;
- $R^3, R^4$  denote H,  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_n$ Het,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nOOOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  $(CH_2)_nN(R^5)C(R^5)HOOR^5$ ,  $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2OOOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$  or  $(CH_2)_nN(R^5)Ar$ , where with the proviso that in each case one of the radicals  $R^3$  or  $R^4$  denotes H,
- $R^5$  denotes H or A,
- A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,
- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more heteroatoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,
- Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $OR^5$ ,  $OOCR^5$ ,  $COOR^5$ ,  $CON(R^5)_2$ , CN,  $NO_2$ ,  $NH_2$ ,  $NHCOR^5$ ,  $CF_3$  or  $SO_2CH_3$ ,
- n denotes 0, 1, 2, 3, 4 or 5,
- Hal denotes F, Cl, Br or I, and
- X denotes N, or

in the case where  $R^1$  denotes




in which R denotes H or an alkyl group having 1 to 6 C atoms,  
and/or R<sup>2</sup>




in which R denotes H or an alkyl group having 1 to 6 C atoms,  
alternatively denotes CH,  
or a pharmaceutically acceptable salt thereof.

20. (Currently Amended) A compound of claim 19, in which Het is one of the following groups



21. (Currently Amended) A compound of formula IA, IB, IC, ID, IE or IF



in which


- $R^1$  denotes ~~H, A, Hal,~~  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms,  ~~$CF_3$ ,  $NO_2$ , CN, C(NH)NOH or  $OCF_3$ ;~~
- $R^2$  denotes  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, or cycloalkyl having 3 to 7 C atoms or  ~~$CF_3$ ,~~
- A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,
- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more heteroatoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,
- Ar denotes a phenyl radical which is unsubstituted or mono- or

R <sup>5</sup>	denotes H or A,
n	denotes 0, 1, 2, 3, 4 or 5,
Hal	denotes F, Cl, Br or I, and
X	denotes N, or

Chemical structures representing various substituents (R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup>, R<sup>26</sup>, R<sup>27</sup>, R<sup>28</sup>, R<sup>29</sup>, R<sup>30</sup>, R<sup>31</sup>, R<sup>32</sup>, R<sup>33</sup>, R<sup>34</sup>, R<sup>35</sup>, R<sup>36</sup>, R<sup>37</sup>, R<sup>38</sup>, R<sup>39</sup>, R<sup>40</sup>, R<sup>41</sup>, R<sup>42</sup>, R<sup>43</sup>, R<sup>44</sup>, R<sup>45</sup>, R<sup>46</sup>, R<sup>47</sup>, R<sup>48</sup>, R<sup>49</sup>, R<sup>50</sup>, R<sup>51</sup>, R<sup>52</sup>, R<sup>53</sup>, R<sup>54</sup>, R<sup>55</sup>, R<sup>56</sup>, R<sup>57</sup>, R<sup>58</sup>, R<sup>59</sup>, R<sup>60</sup>, R<sup>61</sup>, R<sup>62</sup>, R<sup>63</sup>, R<sup>64</sup>, R<sup>65</sup>, R<sup>66</sup>, R<sup>67</sup>, R<sup>68</sup>, R<sup>69</sup>, R<sup>70</sup>, R<sup>71</sup>, R<sup>72</sup>, R<sup>73</sup>, R<sup>74</sup>, R<sup>75</sup>, R<sup>76</sup>, R<sup>77</sup>, R<sup>78</sup>, R<sup>79</sup>, R<sup>80</sup>, R<sup>81</sup>, R<sup>82</sup>, R<sup>83</sup>, R<sup>84</sup>, R<sup>85</sup>, R<sup>86</sup>, R<sup>87</sup>, R<sup>88</sup>, R<sup>89</sup>, R<sup>90</sup>, R<sup>91</sup>, R<sup>92</sup>, R<sup>93</sup>, R<sup>94</sup>, R<sup>95</sup>, R<sup>96</sup>, R<sup>97</sup>, R<sup>98</sup>, R<sup>99</sup>, R<sup>100</sup>, R<sup>101</sup>, R<sup>102</sup>, R<sup>103</sup>, R<sup>104</sup>, R<sup>105</sup>, R<sup>106</sup>, R<sup>107</sup>, R<sup>108</sup>, R<sup>109</sup>, R<sup>110</sup>, R<sup>111</sup>, R<sup>112</sup>, R<sup>113</sup>, R<sup>114</sup>, R<sup>115</sup>, R<sup>116</sup>, R<sup>117</sup>, R<sup>118</sup>, R<sup>119</sup>, R<sup>120</sup>, R<sup>121</sup>, R<sup>122</sup>, R<sup>123</sup>, R<sup>124</sup>, R<sup>125</sup>, R<sup>126</sup>, R<sup>127</sup>, R<sup>128</sup>, R<sup>129</sup>, R<sup>130</sup>, R<sup>131</sup>, R<sup>132</sup>, R<sup>133</sup>, R<sup>134</sup>, R<sup>135</sup>, R<sup>136</sup>, R<sup>137</sup>, R<sup>138</sup>, R<sup>139</sup>, R<sup>140</sup>, R<sup>141</sup>, R<sup>142</sup>, R<sup>143</sup>, R<sup>144</sup>, R<sup>145</sup>, R<sup>146</sup>, R<sup>147</sup>, R<sup>148</sup>, R<sup>149</sup>, R<sup>150</sup>, R<sup>151</sup>, R<sup>152</sup>, R<sup>153</sup>, R<sup>154</sup>, R<sup>155</sup>, R<sup>156</sup>, R<sup>157</sup>, R<sup>158</sup>, R<sup>159</sup>, R<sup>160</sup>, R<sup>161</sup>, R<sup>162</sup>, R<sup>163</sup>, R<sup>164</sup>, R<sup>165</sup>, R<sup>166</sup>, R<sup>167</sup>, R<sup>168</sup>, R<sup>169</sup>, R<sup>170</sup>, R<sup>171</sup>, R<sup>172</sup>, R<sup>173</sup>, R<sup>174</sup>, R<sup>175</sup>, R<sup>176</sup>, R<sup>177</sup>, R<sup>178</sup>, R<sup>179</sup>, R<sup>180</sup>, R<sup>181</sup>, R<sup>182</sup>, R<sup>183</sup>, R<sup>184</sup>, R<sup>185</sup>, R<sup>186</sup>, R<sup>187</sup>, R<sup>188</sup>, R<sup>189</sup>, R<sup>190</sup>, R<sup>191</sup>, R<sup>192</sup>, R<sup>193</sup>, R<sup>194</sup>, R<sup>195</sup>, R<sup>196</sup>, R<sup>197</sup>, R<sup>198</sup>, R<sup>199</sup>, R<sup>200</sup>, R<sup>201</sup>, R<sup>202</sup>, R<sup>203</sup>, R<sup>204</sup>, R<sup>205</sup>, R<sup>206</sup>, R<sup>207</sup>, R<sup>208</sup>, R<sup>209</sup>, R<sup>210</sup>, R<sup>211</sup>, R<sup>212</sup>, R<sup>213</sup>, R<sup>214</sup>, R<sup>215</sup>, R<sup>216</sup>, R<sup>217</sup>, R<sup>218</sup>, R<sup>219</sup>, R<sup>220</sup>, R<sup>221</sup>, R<sup>222</sup>, R<sup>223</sup>, R<sup>224</sup>, R<sup>225</sup>, R<sup>226</sup>, R<sup>227</sup>, R<sup>228</sup>, R<sup>229</sup>, R<sup>230</sup>, R<sup>231</sup>, R<sup>232</sup>, R<sup>233</sup>, R<sup>234</sup>, R<sup>235</sup>, R<sup>236</sup>, R<sup>237</sup>, R<sup>238</sup>, R<sup>239</sup>, R<sup>240</sup>, R<sup>241</sup>, R<sup>242</sup>, R<sup>243</sup>, R<sup>244</sup>, R<sup>245</sup>, R<sup>246</sup>, R<sup>247</sup>, R<sup>248</sup>, R<sup>249</sup>, R<sup>250</sup>, R<sup>251</sup>, R<sup>252</sup>, R<sup>253</sup>, R<sup>254</sup>, R<sup>255</sup>, R<sup>256</sup>, R<sup>257</sup>, R<sup>258</sup>, R<sup>259</sup>, R<sup>260</sup>, R<sup>261</sup>, R<sup>262</sup>, R<sup>263</sup>, R<sup>264</sup>, R<sup>265</sup>, R<sup>266</sup>, R<sup>267</sup>, R<sup>268</sup>, R<sup>269</sup>, R<sup>270</sup>, R<sup>271</sup>, R<sup>272</sup>, R<sup>273</sup>, R<sup>274</sup>, R<sup>275</sup>, R<sup>276</sup>, R<sup>277</sup>, R<sup>278</sup>, R<sup>279</sup>, R<sup>280</sup>, R<sup>281</sup>, R<sup>282</sup>, R<sup>283</sup>, R<sup>284</sup>, R<sup>285</sup>, R<sup>286</sup>, R<sup>287</sup>, R<sup>288</sup>, R<sup>289</sup>, R<sup>290</sup>, R<sup>291</sup>, R<sup>292</sup>, R<sup>293</sup>, R<sup>294</sup>, R<sup>295</sup>, R<sup>296</sup>, R<sup>297</sup>, R<sup>298</sup>, R<sup>299</sup>, R<sup>300</sup>, R<sup>301</sup>, R<sup>302</sup>, R<sup>303</sup>, R<sup>304</sup>, R<sup>305</sup>, R<sup>306</sup>, R<sup>307</sup>, R<sup>308</sup>, R<sup>309</sup>, R<sup>310</sup>, R<sup>311</sup>, R<sup>312</sup>, R<sup>313</sup>, R<sup>314</sup>, R<sup>315</sup>, R<sup>316</sup>, R<sup>317</sup>, R<sup>318</sup>, R<sup>319</sup>, R<sup>320</sup>, R<sup>321</sup>, R<sup>322</sup>, R<sup>323</sup>, R<sup>324</sup>, R<sup>325</sup>, R<sup>326</sup>, R<sup>327</sup>, R<sup>328</sup>, R<sup>329</sup>, R<sup>330</sup>, R<sup>331</sup>, R<sup>332</sup>, R<sup>333</sup>, R<sup>334</sup>, R<sup>335</sup>, R<sup>336</sup>, R<sup>337</sup>, R<sup>338</sup>, R<sup>339</sup>, R<sup>340</sup>, R<sup>341</sup>, R<sup>342</sup>, R<sup>343</sup>, R<sup>344</sup>, R<sup>345</sup>, R<sup>346</sup>, R<sup>347</sup>, R<sup>348</sup>, R<sup>349</sup>, R<sup>350</sup>, R<sup>351</sup>, R<sup>352</sup>, R<sup>353</sup>, R<sup>354</sup>, R<sup>355</sup>, R<sup>356</sup>, R<sup>357</sup>, R<sup>358</sup>, R<sup>359</sup>, R<sup>360</sup>, R<sup>361</sup>, R<sup>362</sup>, R<sup>363</sup>, R<sup>364</sup>, R<sup>365</sup>, R<sup>366</sup>, R<sup>367</sup>, R<sup>368</sup>, R<sup>369</sup>, R<sup>370</sup>, R<sup>371</sup>, R<sup>372</sup>, R<sup>373</sup>, R<sup>374</sup>, R<sup>375</sup>, R<sup>376</sup>, R<sup>377</sup>, R<sup>378</sup>, R<sup>379</sup>, R<sup>380</sup>, R<sup>381</sup>, R<sup>382</sup>, R<sup>383</sup>, R<sup>384</sup>, R<sup>385</sup>, R<sup>386</sup>, R<sup>387</sup>, R<sup>388</sup>, R<sup>389</sup>, R<sup>390</sup>, R<sup>391</sup>, R<sup>392</sup>, R<sup>393</sup>, R<sup>394</sup>, R<sup>395</sup>, R<sup>396</sup>, R<sup>397</sup>, R<sup>398</sup>, R<sup>399</sup>, R<sup>400</sup>, R<sup>401</sup>, R<sup>402</sup>, R<sup>403</sup>, R<sup>404</sup>, R<sup>405</sup>, R<sup>406</sup>, R<sup>407</sup>, R<sup>408</sup>, R<sup>409</sup>, R<sup>410</sup>, R<sup>411</sup>, R<sup>412</sup>, R<sup>413</sup>, R<sup>414</sup>, R<sup>415</sup>, R<sup>416</sup>, R<sup>417</sup>, R<sup>418</sup>, R<sup>419</sup>, R

in which R denotes H or an alkyl group having 1 to 6 C atoms,  
alternatively denotes CH,  
or a pharmaceutically acceptable salt thereof.

22. (Currently Amended) A compound of claim 21, in which Het is one of the following groups



23. (New) A compound of claim 1, in which

$R^1$  denotes Het or Ar,


$R^2$  denotes Het or Ar,

$R^3, R^4$  denote H,  $(CH_2)_nCO_2R^5$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$  or  $(CH_2)_nN(R^5)Ar$ , with the proviso that in each case one of the radicals  $R^3$  or  $R^4$  denotes H,

$R^5$  denotes H or A,

- A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,
- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more heteroatoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,
- Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $\text{OR}^5$ ,  $\text{OOCR}^5$ ,  $\text{COOR}^5$ ,  $\text{CON(R}^5)_2$ , CN,  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{NHCOR}^5$ ,  $\text{CF}_3$  or  $\text{SO}_2\text{CH}_3$ ,
- n denotes 0, 1, 2 or 3,
- Hal denotes F, Cl, Br or I, and
- X denotes N, or

in the case where  $\text{R}^1$  denotes



in which R denotes H or an alkyl group having 1 to 6 C atoms, and/or  $\text{R}^2$  denotes





26. (New) A compound of claim 17, in which the solvate of a compound of formula I is a mono- or dihydrate or alcoholate of the compound of formula I.

27. (New) A method for administering a pharmaceutical composition according to claim 10, comprising providing an effective amount of said pharmaceutical composition to a subject in need thereof.